Clinical Trial Update: Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating fixed-dose flavonoid isoquercetin on thrombo-inflammatory biomarkers in adults with stable sickle cell disease has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Isoquercetin (isoquercetin)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Sickle Cell Disease | Phase 2 | Status: COMPLETED | Results posted: 2023-06-27